$HASI

HASI Maintained by Mizuho -- Price Target Raised to $50

Mizuho maintained its 'Outperform' rating on HA Sustainable Infrastructure Capital (HASI) and raised its price target to $50 from $41. HASI's GF Value™ is $33.87, suggesting a 15.4% overvaluation. The company's P/E (TTM) is 73.74x, higher than its 5-year median of 26.85x. HASI has a GF Score™ of 74/100, indicating strong performance relative to peers.

Original reporting
Published Sep 9, 2026, 2:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 4:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$HASI
Bullish
medium confidence
Mentioned
$HASI
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$HASIBullishMed
01

Why it matters

The target raise could trigger buying pressure, but valuation concerns may cap gains.

02

Market read

The upgrade adds a bullish catalyst for HASI, potentially influencing ESG‑focused portfolios.

03

What to watch

Low financial‑strength rating (2/10) and potential balance‑sheet risks may limit upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst rating updates often precede price moves, especially when price targets are significantly raised.

Company-level read

Ticker impact

$HASIBullishMedium confidence
Context

Mizuho raised its price target for HASI to $50 from $41, maintaining an Outperform rating.

Expected impact

Potential short‑term price appreciation toward the new $50 target.

Evidence & confidence

The 22% target increase reflects confidence in growth, but high valuation metrics temper the upside.

Market effects

May lift sentiment in the sustainable infrastructure and asset‑management space.

Limited to U.S. investors focused on ESG‑oriented funds.

Modest, as the firm is a niche player in the global energy‑transition market.

Counterpoint

The stock appears overvalued with a P/E of 73.7x, suggesting a pull‑back could be warranted.

Key entities

  • Mizuho

    Maintains Outperform rating and raises price target for HASI.

Related articles

$PRGMed

Q2 Rundown: PROG (NYSE:PRG) Vs Other Specialty Finance Stocks

Encore Capital Group (PRG) reported Q2 revenue of $491.9M, up 11.3% YoY, beating estimates. HASI reported $36.32M, down 64.9% YoY, missing estimates. TSLX reported $97.84M, down 14.9% YoY, beating estimates. MAIN reported $149.6M, up 3.9% YoY, topping estimates. PRG stock is up 10.4%, HASI up 8.1%, TSLX up 3.1%, and MAIN up 2.5% since reporting.

$HASIMedAI 8/10

Why Is HA Sustainable Infrastructure Capital (HASI) Stock Soaring Today

HA Sustainable Infrastructure Capital (HASI) shares rose about 7.5% after Q2 results beat expectations and management raised longer-term guidance. Adjusted EPS was $0.75, above forecasts, on revenue of about $120.8 million (+17% YoY). Managed assets grew ~20% to $17.6B. 2028 adjusted EPS guidance increased to $3.55-$3.65 from $3.50-$3.60; shares closed at $40.66 (+6.7%).

$HASIMed

HASI Announces Second Quarter 2026 Results and Raises Guidance on 24% Y/Y Adjusted EPS Growth YTD and Adjusted ROE Above 15%

HA Sustainable Infrastructure Capital, Inc. (HASI) filed an SEC Form 8-K — Results of Operations and Financial Condition. HASI Announces Second Quarter 2026 Results and Raises Guidance on 24% Y/Y Adjusted EPS Growth YTD and Adjusted ROE Above 15% ANNAPOLIS, Md., August 6, 2026 -- (BUSINESS WIRE) -- HA Sustainable Infrastructure Capital, Inc. (“HASI,” “we,” “our” or the “Company”) (NYSE: HASI), a lea

$REGNMed

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

Regeneron Pharmaceuticals reported initial trial results for ubamatamab, showing a 73% objective response rate and 11-month median progression-free survival in 11 patients with advanced low-grade serous ovarian cancer (LGSOC). The company plans to advance the drug into a Phase 3 trial and discuss the data with the FDA. LGSOC is a rare form of ovarian cancer with limited treatment options.